Alector, Inc. — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 65/100
What the filing says
Alector priced an underwritten offering of 36,600,000 shares at $2.05 per share (7.3% premium to Oct 15 close), generating gross proceeds of ~$75.0M. Underwriters: Morgan Stanley and BTIG. Expected close Oct 19, 2026. Investors include TCGX, BVF Partners, ADAR1 Capital, Deep Track Capital. Proceeds for R&D, manufacturing, working capital, and potential acquisitions.
Why this rating
Secondary offering ~65% of market cap. Material capital raise for cash-constrained biotech, but dilutive equity issuance. Meaningful near-term liquidity boost; longer-term significance depends on R&D execution.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.